With fewer patients to absorb the development cost, rare disease treatments usually come with a higher per-patient price tag. With these high prices, the ability to present favorable cost-effectiveness evidence is often low. Assessing the value of these treatments present several unique challenges. Find out more here. (Source: Anupam Jena and Darius Lakdawalla)
You are here: / / Should Value Frameworks for Rare Disease be Different?